Last updated: April 19, 2026

Application No. 18/004,158

MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE SAME AND USES THEREOF

Non-Final OA

Filed

Jan 03, 2023

Examiner

QIAN, CELINE X

Art Unit

1637

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Immunocell Therapeutics Inc.

OA Round

1 (Non-Final)

This examiner grants 48% of cases after interview

— +16.6% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 762 resolved cases, 2023–2026

Examiner Intelligence

QIAN, CELINE X View full profile →

Grants 48% of resolved cases

Career Allow Rate

364 granted / 762 resolved

-12.2% vs TC avg

Strong +17% interview lift

Without

With

+16.6%

Interview Lift

resolved cases with interview

Typical timeline

3y 7m

Avg Prosecution

57 currently pending

Career history

819

Total Applications

across all art units

Statute-Specific Performance

§101

6.6%

-33.4% vs TC avg

§103

29.5%

-10.5% vs TC avg

§102

19.2%

-20.8% vs TC avg

§112

34.3%

-5.7% vs TC avg

Black line = Tech Center average estimate • Based on career data from 762 resolved cases

Prosecution Timeline

Jan 03, 2023

Application Filed

Mar 06, 2026

Non-Final Rejection (current)

Precedent Cases

Applications granted by this same examiner with similar technology

14/414,253

Patent 12584905

METHOD FOR IDENTIFYING MOLECULAR MARKERS OF CHILDREN'S SKIN

2y 5m to grant Granted Mar 24, 2026

17/412,664

Patent 12577561

ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES

2y 5m to grant Granted Mar 17, 2026

18/326,708

Patent 12570972

METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES

2y 5m to grant Granted Mar 10, 2026

17/662,422

Patent 12566177

ANTIGEN AND ANTIBODIES PREPARED BASED ON PADI4 SERVING AS TUMOR MARKER, AND APPLICATION THEREOF

2y 5m to grant Granted Mar 03, 2026

18/461,798

Patent 12565667

CHO INTEGRATION SITES AND USES THEREOF

2y 5m to grant Granted Mar 03, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.

Prosecution Projections

1-2

Expected OA Rounds

48%

Grant Probability

64%

With Interview (+16.6%)

3y 7m

Median Time to Grant

Low

PTA Risk

Based on 762 resolved cases by this examiner. Grant probability derived from career allow rate.